- Home
- QNRX vs DRMA Comparison
QNRX vs DRMA Comparison
Compare QNRX & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- DRMA
- Stock Information
- Founded
- QNRX 2018
- DRMA 2014
- Country
- QNRX United States
- DRMA United States
- Employees
- QNRX N/A
- DRMA N/A
- Industry
- QNRX Medical/Dental Instruments
- DRMA Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- DRMA Health Care
- Exchange
- QNRX Nasdaq
- DRMA Nasdaq
- Market Cap
- QNRX 5.5M
- DRMA 4.5M
- IPO Year
- QNRX N/A
- DRMA 2021
- Fundamental
- Price
- QNRX $8.89
- DRMA $0.71
- Analyst Decision
- QNRX
- DRMA Strong Buy
- Analyst Count
- QNRX 0
- DRMA 1
- Target Price
- QNRX N/A
- DRMA $3.00
- AVG Volume (30 Days)
- QNRX 8.2K
- DRMA 118.5K
- Earning Date
- QNRX 08-07-2025
- DRMA 08-06-2025
- Dividend Yield
- QNRX N/A
- DRMA N/A
- EPS Growth
- QNRX N/A
- DRMA N/A
- EPS
- QNRX N/A
- DRMA N/A
- Revenue
- QNRX N/A
- DRMA N/A
- Revenue This Year
- QNRX N/A
- DRMA N/A
- Revenue Next Year
- QNRX N/A
- DRMA N/A
- P/E Ratio
- QNRX N/A
- DRMA N/A
- Revenue Growth
- QNRX N/A
- DRMA N/A
- 52 Week Low
- QNRX $5.01
- DRMA $0.57
- 52 Week High
- QNRX $54.95
- DRMA $5.00
- Technical
- Relative Strength Index (RSI)
- QNRX 51.38
- DRMA 53.74
- Support Level
- QNRX $8.60
- DRMA $0.61
- Resistance Level
- QNRX $9.40
- DRMA $0.74
- Average True Range (ATR)
- QNRX 0.50
- DRMA 0.06
- MACD
- QNRX -0.05
- DRMA 0.01
- Stochastic Oscillator
- QNRX 46.11
- DRMA 67.43
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.